By Kyle Blankenship
Japanese drugmaker Takeda has quickly emerged as one of the leading forces in the fight against COVID-19 as a vaccine manufacturing partner and R&D lead on a plasma-based therapy. Now, Takeda will help another biotech distribute its potential COVID-19 vaccine in the drugmaker's home country.
read more
By Robert King
The Trump administration announced it will offer a vaccine for COVID-19 at no cost to Medicare beneficiaries when it gets approved, and released a final rule that gives a new add-on payment for hospitals for innovative COVID-19 treatments.
read more
By Angus Liu
Gilead Sciences started charging for remdesivir in July. Given its status then as the only drug authorized for COVID-19 in the U.S., industry watchers immediately forecast multibillion-dollar sales for this year. But new, not-so-promising clinical data now have the Big Biotech in defense mode as analysts dialed down their expectations.
read more
By Robert King
Mergers and acquisitions in healthcare are growing despite the financial crisis caused by the COVID-19 pandemic, with behavioral health and telehealth markets the hottest.
read more
By Eric Sagonowsky,Angus Liu,Kyle Blankenship,Conor Hale,Fraiser Kansteiner
Remdesivir's strong third quarter sales may not extend to the rest of the year, analysts predict. Meanwhile, use of Gilead's drug was up in mid-October, health coordinator CarePort said. Moderna is on track for an interim vaccine review in November. And BioNTech is prepping German vaccine supplies for a swift rollout post-approval.
read more
By Angus Liu
Why do some people get SARS-CoV-2 infection, but others can fight it off? Why do some people develop serious COVID-19 disease after infection, while others only exhibit mild symptoms? A group of scientists from Regeneron has found some clues to those questions from the human genome.
read more
By Tina Reed
Since the start of the COVID-19 pandemic in March, practices have faced reduced volume, decreased revenue and increased expenses which threaten their viability, AMA officials said.
read more
By Heather Landi
The massive financial fallout from the COVID-19 pandemic is a "clarion call" for healthcare providers to shift to new payment models, healthcare leaders say.
read more
By Eric Sagonowsky
Less than a year ago, Sanofi's CEO Paul Hudson unveiled the company's new “play to win” strategy that centers the company on growth drivers such as Dupixent and vaccines. And that strategy delivered in the third quarter as Dupixent posted blockbuster sales and flu vaccines set a revenue record.
read more
